treximet
Commercial- Indications
- migraine with aura, migraine without aura
Company intelligence / Profile preview
Pozen
Chapel Hill, North Carolina, United Statesbobpozen.com ↗
- Ownership
- Private
- Employees
- ~36
- Development stage
- Commercial
01
Overview
Pozen developed several novel combination therapies for pain and cardiovascular indications. Its lead products included Treximet™ (sumatriptan + naproxen sodium) for acute migraine and Yosprala™ (aspirin + omeprazole) for secondary prevention of cardiovascular disease with reduced GI risk. Treximet was approved by the FDA after multiple review cycles; Yosprala was pending approval around the time of acquisition. The company focused on developing drugs through late-stage clinical trials and then licensing or partnering them for commercialization.
- Therapeutic areas
- GastroenterologyCardiovascularNeurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Beyond the preview
Go deeper on Pozen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pozen.